Compare · HEPA vs NVO
HEPA vs NVO
Side-by-side comparison of Hepion Pharmaceuticals Inc. (HEPA) and Novo Nordisk A/S (NVO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both HEPA and NVO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $173.66B, about 2438.2x HEPA ($71.2M).
- HEPA has been more active in the news (6 items in the past 4 weeks vs 3 for NVO).
- NVO has more recent analyst coverage (25 ratings vs 1 for HEPA).
- Company
- Hepion Pharmaceuticals Inc.
- Novo Nordisk A/S
- Price
- $0.32-17.57%
- $38.82-1.05%
- Market cap
- $71.2M
- $173.66B
- 1M return
- +0.00%
- -
- 1Y return
- +0.00%
- -
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- News (4w)
- 6
- 3
- Recent ratings
- 1
- 25
Hepion Pharmaceuticals Inc.
Hepion Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of drug therapy treatment for chronic liver diseases in the United States. It is involved in developing CRV431, a cyclophilin inhibitor that is in Phase 2a clinical trials to target multiple pathologic pathways involved in the progression of liver disease. The company was formerly known as ContraVir Pharmaceuticals, Inc. and changed its name to Hepion Pharmaceuticals, Inc. in July 2019. Hepion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Edison, New Jersey.
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest HEPA
- SEC Form S-8 filed by Hepion Pharmaceuticals Inc.
- Hepion Pharmaceuticals Completes Acquisition of Gravitas Life Sciences and Provides Corporate Update
- SEC Form 8-K filed by Hepion Pharmaceuticals Inc.
- Director Fisher Danina bought $10,000 worth of shares (200,000 units at $0.05) (SEC Form 4)
- Hepion Pharmaceuticals Inc. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
- Hepion Pharmaceuticals Inc. filed SEC Form 8-K: Changes in Registrant's Certifying Accountant, Financial Statements and Exhibits
- New insider Ki Holdings, Ltd. claimed ownership of 10,000,000 shares (SEC Form 3)
- SEC Form SCHEDULE 13G filed by Hepion Pharmaceuticals Inc.
- SEC Form 4 filed by Executive Chairman Lopriore Vincent S
- SEC Form DEF 14C filed by Hepion Pharmaceuticals Inc.
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Novo Nordisk A/S downgraded by Morgan Stanley with a new price target
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Novo Nordisk A/S downgraded by Deutsche Bank